ReviewJournal of asthma and allergy2026
Potential Determinants of Progression from Cough-Variant Asthma to Classic Asthma in Children: Evidence, Mechanisms, and Clinical Research Gaps.
Review in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To synthesize current evidence on host and environmental factors potentially associated with progression of cough variant asthma (CVA) to classic asthma in children, with explicit distinction between direct evidence from pediatric CVA cohorts and indirect evidence extrapolated from general asthma or adult studies, and to identify research gaps for future investigation. Data Sources: PubMed, EMBASE, and Web of Science were searched for studies examining CVA progression, risk factors, and mechanisms in pediatric populations. Study Selections: Original research articles, meta-analyses, and systematic reviews investigating genetic susceptibility, atopy, airway hyperresponsiveness, medication adherence, diet, psychological stress, respiratory infections, allergen exposure, and indoor air pollution in relation to CVA-to-classic asthma progression in children aged <18 years were included. Results: Atopy and airway hyperresponsiveness carry the most consistent evidence. Poor medication adherence is the most readily modifiable risk factor. Environmental triggers include respiratory viral infections (particularly rhinovirus), allergen exposure, and indoor air pollution. These factors converge on Th2-biased immunity, epithelial barrier dysfunction, neuroimmune interactions, and epigenetic reprogramming. A nomogram integrating clinical variables and biomarkers achieved AUCs of 0.929 and 0.914 in training and validation cohorts, respectively, but validated prediction tools for CVA progression remain unavailable. Conclusion: Early identification of high-risk children through integrated clinical and biomarker assessment, combined with comprehensive management targeting modifiable risk factors, remains the most rational approach to symptom control, exacerbation prevention, and preservation of lung function; whether this delays progression awaits validation in pediatric interventional trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.